Find safe dose for Parkinson
- Trial ID
- NCT06189170
- Official Title
- A Phase I, Randomised, Double-Blinded, Placebo-Controlled Study to Evaluate KP405. Part 1: Single Ascending Dosing in Healthy Participants. Part 2: Multiple Ascending Dosing in Healthy Participants and Parkinson's Disease Patients.
- Goal
- Find safe dose for Parkinson
- Phase
- EARLY_PHASE1
- Status
- RECRUITING
- Sponsor
- Kariya Pharmaceuticals
- Study Type
- INTERVENTIONAL
- Enrollment
- 88 participants
- Conditions
- Safety Issues, Tolerance
- Interventions
- KP405, Placebo
Plain-Language Summary
The trial is aiming to establish whether KP405 is safe and well tolerated, and to find appropriate dose ranges before any larger Parkinson's studies. Participants receive single and then multiple escalating doses of KP405 or placebo, so researchers can track how the drug is handled by the body, what side effects appear, and whether it is tolerated alongside usual Parkinson's care such as levodopa. Adults aged 18 to 80 are being recruited, including healthy volunteers and people with Parkinson's who meet UK Brain Bank criteria, while people with other significant neurological or unstable medical conditions are excluded.
Locations
- MAC, Manchester, United Kingdom
Frequently Asked Questions
- What is this trial testing?
- This trial is studying KP405. The trial is aiming to establish whether KP405 is safe and well tolerated, and to find appropriate dose ranges before any larger Parkinson's studies. Participants receive single and then multiple escalating doses of KP405 or placebo, so researchers can track how the drug is handled by the body, what side effects appear, and whether it is tolerated alongside usual Parkinson's care such as levodopa. Adults aged 18 to 80 are being recruited, including healthy volunteers and people with Parkinson's who meet UK Brain Bank criteria, while people with other significant neurological or unstable medical conditions are excluded.
- Who can participate?
- Participants must be between 18 Years and 80 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This Phase 1 trial is estimated to last approximately 1 year and 5 months.